Phreesia (NYSE:PHR) Sets New 1-Year Low on Disappointing Earnings

Key Points

• Phreesia reported Q earnings of $0.02 EPS versus a $0.07 consensus (a $0.05 miss) on revenue of $127.07M (+15.9% YoY), and the stock plunged to a new 52-week low, trading down roughly 24–26% intraday to about $8.07.
• Management cut FY2027 revenue guidance to $510–$520M (from $545–$559M) citing weaker pharma client visibility, prompting analyst price-target cuts and downgrades that increased near-term selling pressure.

Phreesia, Inc. (NYSE:PHR - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Tuesday following a dissappointing earnings announcement. The stock traded as low as $8.23 and last traded at $8.0690, with a volume of 261246 shares. The stock had previously closed at $11.41.

The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.05). The firm had revenue of $127.07 million during the quarter, compared to the consensus estimate of $126.75 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The company's revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.11) earnings per share.

Trending Headlines about Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Several brokers kept buy/outperform stances or price targets above the current level, implying upside and supporting a rebound: BMO kept an "outperform" rating with a $14 target. Benzinga
• Positive Sentiment: Canaccord Genuity reiterated a "buy" rating despite lowering its target to $22, signaling confidence in longer-term upside. Benzinga
• Positive Sentiment: Needham kept a "buy" rating while cutting its target to $14, another vote that some analysts view the stock as attractive after the pullback. Benzinga
• Neutral Sentiment: Company results: Q4 revenue of about $127M (+15.9% YoY) and fiscal-year operating/cash-flow milestones were reported, but quarter-level EPS and metric headlines were mixed across sources (some headline misses, some call transcripts indicating beats), leaving clarity for investors dependent on the call/slide details. Press Release / Slide Deck
• Negative Sentiment: Management cut FY2027 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the earlier steep share decline. Benzinga Guide Cut Article
• Negative Sentiment: Multiple analysts downgraded or cut price targets after the guidance cut — Robert W. Baird and Citigroup reaffirmed neutral/hold views with $10 targets, and Truist held at $11 — increasing near-term selling pressure and lowering consensus valuation expectations. TickerReport
• Negative Sentiment: Market reaction: headlines show shares plunged ~22–26% immediately after the results/guidance, indicating heightened short-term risk and potential for continued volatility. MSN

Analyst Ratings Changes

Several equities research analysts recently weighed in on PHR shares. Robert W. Baird restated a "neutral" rating and issued a $10.00 price target (down from $25.00) on shares of Phreesia in a research report on Tuesday. Weiss Ratings restated a "sell (e+)" rating on shares of Phreesia in a report on Wednesday, January 28th. Zacks Research cut shares of Phreesia from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, January 6th. Citigroup reiterated a "neutral" rating and issued a $10.00 price target on shares of Phreesia in a research report on Tuesday. Finally, DA Davidson lowered their price objective on Phreesia from $35.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, January 23rd. Thirteen equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $22.00.

Insider Buying and Selling

In other Phreesia news, insider Evan Roberts sold 6,268 shares of the company's stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $16.36, for a total value of $102,544.48. Following the transaction, the insider directly owned 826,554 shares in the company, valued at $13,522,423.44. This represents a 0.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Allison C. Hoffman sold 6,176 shares of the firm's stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $11.97, for a total transaction of $73,926.72. Following the transaction, the general counsel directly owned 163,485 shares in the company, valued at approximately $1,956,915.45. This trade represents a 3.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 70,358 shares of company stock worth $1,123,569 over the last 90 days. Corporate insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On Phreesia

A number of institutional investors and hedge funds have recently bought and sold shares of PHR. Federated Hermes Inc. purchased a new stake in shares of Phreesia in the 3rd quarter worth $32,000. Van ECK Associates Corp raised its holdings in shares of Phreesia by 78.7% in the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company's stock valued at $42,000 after acquiring an additional 1,102 shares in the last quarter. Asset Management One Co. Ltd. purchased a new stake in Phreesia in the third quarter worth about $45,000. Rockefeller Capital Management L.P. lifted its stake in Phreesia by 354.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company's stock worth $47,000 after acquiring an additional 2,149 shares during the period. Finally, KBC Group NV grew its holdings in Phreesia by 83.4% during the 4th quarter. KBC Group NV now owns 3,449 shares of the company's stock worth $58,000 after acquiring an additional 1,568 shares in the last quarter. 92.10% of the stock is owned by institutional investors.

Phreesia Trading Down 24.9%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The company has a market capitalization of $516.87 million, a P/E ratio of -84.27 and a beta of 0.67. The company's fifty day simple moving average is $12.51 and its 200-day simple moving average is $17.68.

About Phreesia

Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.